Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer

  • Authors:
    • Zhiguang Gao
    • Bomin Guo
    • Renyuan Gao
    • Qingchao Zhu
    • Wen Wu
    • Huanlong Qin
  • View Affiliations

  • Published online on: July 27, 2015     https://doi.org/10.3892/mmr.2015.4124
  • Pages: 6119-6127
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Studies using animal models have demonstrated that probiotics may have a beneficial role in the prevention of colorectal cancer (CRC); however, the underlying mechanism of the beneficial effects of interventional probiotic treatment on gut microbiota has remained elusive. In the present study, pyrosequencing of the V3 region of the 16S rRNA genes was conducted in order to determine the extent to which probiotics alter the microbiota. The observations of the present study indicated that the microbial structure of cancerous tissue differed significantly from that of healthy individuals and that the CRC microbiota exhibited lower diversity. It was indicated that interventional treatment with probiotics increased the density and diversity of mucosal microbes, and altered the mucosa‑associated microbiota. Pyrosequencing demonstrated that probiotics significantly reduced (5‑fold) the abundance of a bacterial taxon assigned to the genus Fusobacterium, which had been previously suggested to be a contributing factor to increase tumorigenesis. Accordingly, interventional probiotic therapy is suggested to be able to improve the composition of the mucosal microbial flora and significantly reduce the abundance of mucosa-associated pathogens in patients with CRC.

References

1 

Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI

2 

Li D, Wu C, Zheng Y, Zhong W and Wu F: Incidence and mortality of colorectal cancer in Shanghai from 2003 to 2007. Zhongguo Zhongliu. 20:413–418. 2011.

3 

Woolf CM: A genetic study of carcinoma of the large intestine. Am J Hum Genet. 10:42–47. 1958.PubMed/NCBI

4 

Winawer SJ, Zauber AG, Gerdes H, O'Brien MJ, Gottlieb LS, Sternberg SS, Bond JH, Waye JD, Schapiro M and Panish JF: Risk of colorectal cancer in the families of patients with adenomatous polyps National Polyp Study Workgroup. N Engl J Med. 334:82–87. 1996. View Article : Google Scholar : PubMed/NCBI

5 

Magrone T and Jirillo E: The interaction between gut microbiota and age-related changes in immune function and inflammation. Immun Ageing. 10:312013. View Article : Google Scholar : PubMed/NCBI

6 

O'Toole PW: Changes in the intestinal microbiota from adulthood through to old age. Clin Microbiol Infect. 18:44–46. 2012. View Article : Google Scholar : PubMed/NCBI

7 

DiBaise JK, Frank DN and Mathur R: Impact of the gut microbiota on the development of obesity: Current concepts. Am J Gastroenterol. 1(Suppl): 22–27. 2012. View Article : Google Scholar

8 

Kallus SJ and Brandt LJ: The intestinal microbiota and obesity. J Clin Gastroenterol. 46:16–24. 2012. View Article : Google Scholar

9 

Rubinstein MR, Wang X, Liu W, Hao Y, Cai GF and Han YW: Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating e-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 14:195–206. 2013. View Article : Google Scholar : PubMed/NCBI

10 

Sobhani I, Amiot A, Le Baleur Y, Levy M, Auriault M, Van Nhieu JT and Delchier JC: Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease? Therap Adv Gastroenterol. 6:215–229. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Tjalsma H, Boleij A, Marchesi JR and Dutilh BE: A bacterial driver-passenger model for colorectal cancer: Beyond the usual suspects. Nat Rev Microbiol. 10:575–582. 2012. View Article : Google Scholar : PubMed/NCBI

12 

Ley RE, Peterson DA and Gordon JI: Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 124:837–848. 2006. View Article : Google Scholar : PubMed/NCBI

13 

Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G, Ojetti V, Scarpellini E and Gasbarrini A: The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci. 17:323–333. 2013.PubMed/NCBI

14 

Xu X, Xu P, Ma C, Tang J and Zhang X: Gut microbiota, host health and polysaccharides. Biotechnol Adv. 31:318–337. 2013. View Article : Google Scholar : PubMed/NCBI

15 

Compare D and Nardone G: The bacteria-hypothesis of colorectal cancer: Pathogenetic and therapeutic implications. Transl Gastrointest Cancer. 3:44–53. 2014.

16 

Rowland I: Probiotics and colorectal cancer risk. Br J Nutr. 91:805–807. 2004. View Article : Google Scholar : PubMed/NCBI

17 

Uccello M, Malaguarnera G, Basile F, D'agata V, Malaguarnera M, Bertino G, Vacante M, Drago F and Biondi A: Potential role of probiotics on colorectal cancer prevention. BMC Surg. 12:S352012. View Article : Google Scholar : PubMed/NCBI

18 

Delia P, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C and Famularo G: Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol. 13:912–915. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Famularo G, Mosca L, Minisola G, Trinchieri V and De Simone C: Probiotic lactobacilli: A new perspective for the treatment of inflammatory bowel disease. Curr Pharm Des. 9:1973–1980. 2003. View Article : Google Scholar : PubMed/NCBI

20 

Ljungh A and Wadström T: Lactic acid bacteria as probiotics. Curr Issues Intest Microbiol. 7:73–89. 2006.PubMed/NCBI

21 

Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, Dhar A, Brown H, Foden A, Gravenor MB, et al: Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 382:1249–1257. 2013. View Article : Google Scholar : PubMed/NCBI

22 

Mackowiak PA: Recycling metchnikoff: Probiotics, the intestinal microbiome and the quest for long life. Front Public Health. 1:522013. View Article : Google Scholar : PubMed/NCBI

23 

Allen SJ, Martinez EG, Gregorio GV and Dans LF: Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 10:CD0030482010.

24 

Chen CC, Kong MS, Lai MW, Chao HC, Chang KW, Chen SY, Huang YC, Chiu CH, Li WC, Lin PY, et al: Probiotics have clinical, microbiologic and immunologic efficacy in acute infectious diarrhea. Pediatr Infect Dis J. 29:135–138. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B and Shekelle PG: Probiotics for the prevention and treatment of antibiotic-associated diarrhea a systematic review and meta-analysis. JAMA. 307:1959–1969. 2012. View Article : Google Scholar : PubMed/NCBI

26 

Koebnick C, Wagner I, Leitzmann P, Stern U and Zunft HJ: Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol. 17:655–659. 2003.PubMed/NCBI

27 

Ouwehand AC, Lagström H, Suomalainen T and Salminen S: Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab. 46:159–162. 2002. View Article : Google Scholar : PubMed/NCBI

28 

de Milliano I, Tabbers MM, van der Post JA and Benninga MA: Is a multispecies probiotic mixture effective in constipation during pregnancy? 'A pilot study'. Nutr J. 11:802012. View Article : Google Scholar : PubMed/NCBI

29 

Persborn M and Söderholm JD: Commentary: the effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis-authors' reply. Aliment Pharmacol Ther. 38:1406–1407. 2013. View Article : Google Scholar : PubMed/NCBI

30 

Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, et al: Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic Vs.L#3 as adjunctive to a standard pharmaceutical treatment: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 105:2218–2227. 2010. View Article : Google Scholar : PubMed/NCBI

31 

Müllner K, Miheller P, Herszényi L and Tulassay Z: Probiotics in the management of Crohn's disease and ulcerative colitis. Curr Pharm Des. 20:4556–4560. 2014. View Article : Google Scholar

32 

Huebner C, Ding Y, Petermann I, Knapp C and Ferguson LR: The probiotic Escherichia coli Nissle 1917 reduces pathogen invasion and modulates cytokine expression in Caco-2 cells infected with Crohn's disease-associated E. coli LF82. Appl Environ Microbiol. 77:2541–2544. 2011. View Article : Google Scholar : PubMed/NCBI

33 

Kõljalg U, Nilsson RH, Abarenkov K, Tedersoo L, Taylor AF, Bahram M, Bates ST, Bruns TD, Bengtsson-Palme J, Callaghan TM, et al: Towards a unified paradigm for sequence-based identification of fungi. Mol Ecol. 22:5271–5277. 2013. View Article : Google Scholar : PubMed/NCBI

34 

Hamady M, Walker JJ, Harris JK, Gold NJ and Knight R: Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex. Nat Methods. 5:235–237. 2008. View Article : Google Scholar : PubMed/NCBI

35 

Edgar RC: UPARSE: Highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 10:996–998. 2013. View Article : Google Scholar : PubMed/NCBI

36 

Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J and Glöckner FO: The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools. Nucleic Acids Res. 41:D590–D596. 2013. View Article : Google Scholar :

37 

DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Dalevi D, Hu P and Andersen GL: Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 72:5069–5072. 2006. View Article : Google Scholar : PubMed/NCBI

38 

Appleyard CB, Cruz ML, Isidro AA, Arthur JC, Jobin C and De Simone C: Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer. Am J Physiol Gastrointest Liver Physiol. 301:G1004–G1013. 2011. View Article : Google Scholar : PubMed/NCBI

39 

Fotiadis CI, Stoidis CN, Spyropoulos BG and Zografos ED: Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer. World J Gastroenterol. 14:6453–6457. 2008. View Article : Google Scholar : PubMed/NCBI

40 

Wollowski I, Rechkemmer G and Pool-Zobel BL: Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr. 73:451S–455S. 2001.PubMed/NCBI

41 

Bertkova I, Hijova E, Chmelarova A, Mojzisova G, Petrasova D, Strojny L, Bomba A and Zitnan R: The effect of probiotic microorganisms and bioactive compounds on chemically induced carcinogenesis in rats. Neoplasma. 57:422–428. 2010. View Article : Google Scholar : PubMed/NCBI

42 

Vipperla K and O'Keefe SJ: The microbiota and its metabolites in colonic mucosal health and cancer risk. Nutr Clin Pract. 27:624–635. 2012. View Article : Google Scholar : PubMed/NCBI

43 

Wang J, Tang H, Zhang C, Zhao Y, Derrien M, Rocher E, van-Hylckama Vlieg JE, Strissel K, Zhao L, Obin M and Shen J: Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME. 9:1–15. 2015. View Article : Google Scholar

44 

Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, et al: Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22:292–298. 2012. View Article : Google Scholar :

45 

Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S and Zhao L: Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 6:320–329. 2012. View Article : Google Scholar :

46 

Allen-Vercoe E, Strauss J and Chadee K: Fusobacterium nucleatum: An emerging gut pathogen? Gut Microbes. 2:294–298. 2011. View Article : Google Scholar : PubMed/NCBI

47 

Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devinney R, Lynch T and Allen-Vercoe E: Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 17:1971–1978. 2011. View Article : Google Scholar : PubMed/NCBI

48 

Arthur JC and Jobin C: The struggle within: Microbial influences on colorectal cancer. Inflamm Bowel Dis. 17:396–409. 2011. View Article : Google Scholar

49 

Chaikham P and Apichartsrangkoon A: Effects of encapsulated Lactobacillus acidophilus along with pasteurized longan juice on the colon microbiota residing in a dynamic simulator of the human intestinal microbial ecosystem. Appl Microbiol Biotechnol. 98:485–495. 2014. View Article : Google Scholar

Related Articles

Journal Cover

October 2015
Volume 12 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Gao, Z., Guo, B., Gao, R., Zhu, Q., Wu, W., & Qin, H. (2015). Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer. Molecular Medicine Reports, 12, 6119-6127. https://doi.org/10.3892/mmr.2015.4124
MLA
Gao, Z., Guo, B., Gao, R., Zhu, Q., Wu, W., Qin, H."Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer". Molecular Medicine Reports 12.4 (2015): 6119-6127.
Chicago
Gao, Z., Guo, B., Gao, R., Zhu, Q., Wu, W., Qin, H."Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer". Molecular Medicine Reports 12, no. 4 (2015): 6119-6127. https://doi.org/10.3892/mmr.2015.4124